Dr Catherine Mummery on UCL’s groundbreaking research into gene silencing treatments

Dr Catherine Mummery is the head of novel therapeutics at the UCL Dementia Research Centre and is also a consultant neurologist at the National Hospital for Neurology and Neurosurgery. 

She is leading a world-first trial involving a ‘gene silencing’ drug (BIIB080) that has shown promise in safely and successfully lowering levels of the harmful tau protein known to cause Alzheimer's disease.

Alongside her work in finding new treatments, Dr Mummery is also working on a groundbreaking trial that would enable MRI scans to be completed in a fraction of the time they currently are. She explains the importance of this in the following video:

 

Links:

• View Dr Catherine Mummery's Academic Profile
• View Dr Mummery's UCLH Profile
• Read about the work of the UCL Dementia Research Centre
• UCL news piece on the first ‘gene silencing’ drug for Alzheimer’s disease showing promise

Biography

Catherine Mummery studied medicine at UCH, trained in neurology at NHNN and Kings College Hospital, and gained a PhD in cognitive neurology at the Wellcome Department of Functional Imaging, UCL.

She is head of novel therapeutics at the Dementia Research Centre, UCL and has been senior investigator on over 20 early phase drug trials of disease modifying agents in dementias including genetic forms of Alzheimer’s disease and frontotemporal dementia. She is deputy director for the Leonard Wolfson Experimental Neurology Centre at NHNN, a unit dedicated to early phase trials in neurodegeneration.

She was elected to the executive of the Association of British neurologists as services chair in 2017 and also works closely with the Royal College of Physicians, sitting on the medical specialties board and chairing the joint clinical neurosciences committee. As deputy director of the NHSE Neurosciences Clinical Reference Group, she is closely involved in work to enhance neurology care for patients.